Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation
We sat down with Dorothy McCabe, PhD, the executive director of clinical development and medical affairs, immunology and biosimilars at Boehringer Ingelheim Pharmaceuticals and co-chair of the Biosimilars Forum education committee, to discuss what more needs to be done to combat biosimilar misinformation and how patients and physicians can help the cause.
Welcome to Not So Different, a podcast from The Center for Biosimilars®. I’m your host, Assistant Editor Skylar Jeremias.
A recently published opinion piece from 2 executives of Sandoz and Boehringer Ingelheim argued that misinformation is weakening patient and physician trust in biosimilars, preventing access to these lower-cost biologics, and slowing their uptake in the United States. The authors also called for changes in standard biosimilar terminology that they say misleads the public about the safety and use of these products.
We sat down with an author of the opinion piece, Dorothy McCabe, PhD, the executive director of clinical development and medical affairs, immunology and biosimilars at Boehringer Ingelheim Pharmaceuticals and co-chair of the Biosimilars Forum education committee, to discuss what more needs to be done to combat biosimilar misinformation and how patients and physicians can help the cause.
To learn more about the opinion piece McCabe co-authored, click here.
To learn more about Boehringer Ingelheim, visit boehringer-ingelheim.com.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.
Not So Different: Kathy Oubre on What Oncology Practices Have Lacked During the Pandemic
October 18th 2020We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center, to discuss what practices have had to forgo during the coronavirus disease 2019 (COVID-19) crisis and how biosimilar access has been affected.
